A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy

Inclusion Criteria: * Patients with AML receiving non-intensive therapy including hypomethylating agents, single-agent chemotherapy, targeted therapy agents, or single or combination non-intensive agents offered on a clinical trial, including the following populations: * Newly diagnosed AML * Relapsed AML * Primary refractory AML * The ability to provide informed consent * The ability to comprehend English or complete questionnaires with minimal assistance of an interpreter Exclusion Criteria: * Patients not receiving care at MGH * Patients receiving intensive chemotherapy (requiring 4-6 week hospitalization) * Patients receiving supportive care alone * Major psychiatric illness or co-morbid conditions prohibiting compliance with study procedures * Patients already receiving palliative care